BRAF and non-small cell lung carcinoma: Currently, the standard diagnostic method approved by the FDA is the next-generation sequencing oncology panel test (OncomineTM Dx Target Test, Thermo Fisher Scientific Inc. USA), which has been shown to accurately and reliably detect patients with NSCLC carrying the BRAF V600E mutation [10].